What antibiotics are recommended for bacterial keratitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Antibiotic Treatment for Bacterial Keratitis

For bacterial keratitis, initiate treatment with topical fluoroquinolone monotherapy (ciprofloxacin 0.3%, ofloxacin 0.3%, or levofloxacin 1.5%) for mild-to-moderate cases, or fortified antibiotics (cefazolin + tobramycin or vancomycin + ceftazidime) for severe cases with central involvement, deep stromal infiltration, infiltrates >2mm, or hypopyon. 1

Treatment Algorithm Based on Severity

Mild-to-Moderate Keratitis (Small, Non-Central Ulcers)

Fluoroquinolone monotherapy is the first-line treatment:

  • FDA-approved options: Ciprofloxacin 0.3%, ofloxacin 0.3%, or levofloxacin 1.5% 1
  • Dosing: Apply every 1-2 hours while awake initially, then taper based on response
  • Efficacy: Single fluoroquinolone therapy is as effective as fortified combination therapy for most community-acquired cases 1

Fourth-generation fluoroquinolones (moxifloxacin, gatifloxacin) offer superior gram-positive coverage and may heal faster:

  • Recent network meta-analysis shows moxifloxacin heals 6.81 days faster than ciprofloxacin 2
  • Better coverage against methicillin-resistant Staphylococcus than earlier fluoroquinolones 1
  • Not FDA-approved for bacterial keratitis but perform as well or better than standard therapy in clinical trials 1

Severe Keratitis (Central Location, Deep Stromal Involvement, Infiltrate >2mm, or Hypopyon)

Fortified antibiotic combination therapy is preferred:

Best options based on 2025 network meta-analysis 2:

  1. Vancomycin + ceftazidime (fastest healing, SUCRA 83.8; fewest adverse effects, SUCRA 93.1)
  2. Cefazolin + tobramycin (SUCRA 71.3 for healing)
  3. Cefazolin + gentamicin (low adverse effects, SUCRA 82.5)

Dosing for severe cases 1:

  • Loading dose: Every 5-15 minutes for first hour
  • Maintenance: Every hour around the clock initially
  • Continue until clinical improvement confirmed, then taper

Critical Resistance Considerations

Fluoroquinolone resistance is increasing 1:

  • 42% of Staphylococcal isolates show methicillin resistance with concurrent fluoroquinolone resistance 1
  • Risk factors: Recent fluoroquinolone use, hospitalization, advanced age, recent ocular surgery 1
  • Streptococci and anaerobes have variable fluoroquinolone susceptibility 1
  • Pseudomonas resistance to moxifloxacin increased from 19% to 52% in some regions 1

When resistance is suspected, switch to fortified antibiotics immediately rather than continuing ineffective fluoroquinolone therapy.

Adjunctive Measures

Cycloplegics: Use to reduce pain and prevent synechiae formation 1

Systemic antibiotics: Reserve for:

  • Scleral extension
  • Intraocular extension
  • Impending/frank perforation
  • Gonococcal keratitis (mandatory) 1

Corticosteroids: May add after 2-3 days of antibiotic therapy IF:

  • Organism identified (NOT Nocardia or fungus)
  • Epithelial defect healing
  • Ulcer consolidating
  • Central corneal involvement threatening vision 1

Common Pitfalls to Avoid

  1. Don't use ointments as primary therapy - poor corneal penetration; reserve for bedtime in mild cases 1
  2. Don't patch contact lens-related abrasions - increases bacterial keratitis risk 1
  3. Don't add corticosteroids to Nocardia infections - results in poor visual outcomes 1
  4. Don't delay fortified antibiotics in severe cases - higher MIC correlates with worse outcomes 1
  5. Don't assume fourth-generation fluoroquinolones work for Pseudomonas - resistance rates are high in some regions 1

Follow-Up Intensity

  • Severe cases: Daily evaluation until stable improvement confirmed 1
  • Mild-to-moderate cases: Every 2-3 days initially, adjust based on response

References

Related Questions

What is the initial treatment for a contact‑lens wearer presenting with presumed bacterial keratitis?
For a typical adult with a mild-to-moderate bacterial ocular infection, how many days should therapy be administered?
Which topical antibiotics are appropriate for treating an ocular surface infection?
Should I change the topical antibiotic from erythromycin to a broad‑spectrum fluoroquinolone for a patient with a large corneal abrasion who now has blurred vision and fluorescein staining showing corneal and peri‑ocular uptake?
What is the recommended ophthalmic treatment for keratitis?
What are the recommended lisinopril dosing guidelines for adults with hypertension and heart failure, including dose adjustments for elderly, volume‑depleted, or renally impaired patients?
What functional activities should a 63-year-old patient be able to perform after a transforaminal lumbar interbody fusion (TLIF) procedure?
What are the possible causes of painless popping in the knee?
Does a low or high dietary calcium intake influence the risk of calcium oxalate kidney stones?
What key concepts about disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and sepsis should an ICU nurse understand when preparing for a CRNA (certified registered nurse anesthetist) interview?
What is the recommended management for a patient with confirmed TYK2 deficiency that impairs cytokine signaling downstream of receptors, including the IL‑23 pathway, and reduces Th17 function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.